- Market Intelligence
- Enterprise Platform
- News Data Feeds API
- Executive Briefings
- About Us
- Contact Us
- Case Studies
- Data Sheets
New Jersey’s Attorney General filed a lawsuit Tuesday against Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, for misleading patients and prescribers about the addictive risks associated with the use of its drugs. The complaint alleges that Janssen is actively contributing to the opioid crisis by aggressively and inaccurately marketing their opioid drugs.
The UK Supreme Court ruled Thursday against pharmaceutical company Pfizer in a patent case over its drug Lyrica. The case involved secondary usage of a known and patented pharmaceutical compound—applying an already patented pharmaceutical compound to a new use.
Glenmark Pharmaceuticals Thursday said it has received approval from the US health regulator for Teriflunomide tablets used to treat multiple sclerosis. The approved product is generic version of Sanofi-Aventis US' Aubagio. Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Teriflunomide tablets in the strengths of 7 mg and 14 mg, the company said in a BSE filing.
SOMERSET, N.J. November 15, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Pete Young, Director of Quality at Catalent’s Bolton, U.K.
By Daniel Siegal Law360 (November 15, 2018, 7:37 PM EST) -- The second South Carolina jury to try and decide if a 30-year-old attorney's fatal mesothelioma was caused by alleged asbestos in Johnson & Johnson
Belgian biopharma company UCB has tapped customer engagement company Verint Systems to create an app for patients with Parkinson's disease. The app is called PD Coach and includes an AI assistant named April which can communicate with users either by text or speech.
Posted 15 November 2018 | By Zachary Brennan Building off a Pfizer citizen petition on biosimilar misinformation, Novartis is calling on FDA to set the record straight on what information can be disseminated.The misinformation campaigns,
A Swedish drugmaker focused on rare diseases has bought US rights to an AstraZeneca drug. Sobi, a Stockholm-based firm whose name stands for Swedish Orphan Biovitrium AB said Tesday that it had acquired perpetual US rights to AstraZeneca’s Synagis (palivizumab), along with rights to receive 50 percent of US earnings from the investigational AstraZeneca drug MEDI8897.
FILE PHOTO: A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo ZURICH (Reuters) - Novartis launched a copy of Johnson & Johnson’s (J&J) inflammation-fighting Remicade in Germany on Thursday as the Swiss drugmaker aims to catch rival biosimilars that are already available in Europe’s largest healthcare market.
Pfizer launches anemia biosimilar at 33% discount Pfizer launched a sharply discounted biosimilar of Epogen, a treatment for anemia produced by Amgen, and Procrit, produced by Johnson & Johnson, according to The Center for Biosimilars. Pfizer sent its first shipment of Retacrit to wholesalers Nov.
Thesis AbbVie (ABBV) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend looks very safe for the foreseeable future.
Allen & Overy (A&O) client Pfizer has lost a landmark Supreme Court battle against a host of manufacturers, leaving it vulnerable to substantial financial claims. In a judgment handed down yesterday (14 November), the Supreme Court upheld lower court decisions that Pfizer’s patent for its pregabalin pain relief product was invalid.
Merck’s Keytruda is looking to beat its immuno-oncology rivals into yet another market, and it just posted the data that could get the job done. On Wednesday, the New Jersey drugmaker said that in a phase 3 study pitting its star against chemo, Keytruda had lengthened the lives of previously treated esophageal or esophagogastric junction carcinoma patients whose tumors expressed certain levels of biomarker PD-L1.
Boehringer Ingelheim will collaborate with Epizyme (NASDAQ:EPZM) on developing and commercializing two small molecule inhibitors of unaddressed epigenetic targets in oncology. Specifically, the targets are helicase and histone acetyltransferase (HAT) enzymes that play key roles in cancer development when dysregulated.
AbbVie (NYSE:ABBV) inks a collaboration agreement with Mission Therapeutics aimed at developing deubiquitylating enzymes (DUBs) for the potential treatment of Alzheimer's disease and Parkinson's disease. DUBs play a key role in maintaining cellular health by regulating the degradation of misfolded toxic proteins which are believed to cause impaired function and death of nerve cells in the brain.
Exelixis (NASDAQ:EXEL) announces that collaboration partner Ipsen (OTCPK:IPSEF) has received marketing approval from the European Commission for CABOMETYX (cabozantinib) as monotherapy in adult patients with hepatocellular carcinoma who have been previously treated with Bayer's Nexavar (sorafenib).
Sanofi cuts 160 jobs in Tennessee As part of a U.S. restructuring effort, biopharmacutical company Sanofi will cut 160 jobs at its facility in Chattanooga, Tenn., according to the Chattanooga Times Free Press. The affected jobs, which include positions in marketing, sales, research and development and some support functions, will move to New Jersey as the drugmaker reorganizes its consumer healthcare business.